Jagsonpal Pharmaceuticals H1FY27 Profit Up 10.3% to ₹258 Cr; Consolidated Revenue Grows 29%
Jagsonpal Pharmaceuticals reported H1FY27 standalone PAT up 10.3% to ₹258 million. Q2FY27 consolidated revenue grew 29% to ₹964 million, with standalone revenue up 9.3%. The company holds ₹1,347 million cash. Two acquisitions, Aequitas Healthcare and Group Pharma's Wellness Portfolio, were completed, supporting the Mission 2028 revenue target of ₹5,000 million.
The announcement includes strong financial performance metrics, details on strategic acquisitions that expand market reach and product portfolio, and a clear future growth strategy with ambitious revenue targets, all of which are material to investors.
The company reported significant year-on-year growth in consolidated revenue and a healthy increase in profit, along with strategic acquisitions and a clear roadmap for future growth, indicating positive performance and outlook.
Jagsonpal Pharmaceuticals Limited has announced its financial results for the quarter and half-year ended September 30, 2026. Consolidated revenue for Q2FY27 surged by 29% to ₹964 million, while the standalone business saw a 9.3% increase. For the half-year ended H1FY27, net profit grew by 10.3%. The company maintained a strong cash position of ₹1,347 million as of September 30, 2026, after an enhanced dividend payout of 200% in September.
On a standalone basis for Q2FY27, revenue stood at ₹814 million, with EBITDA at ₹185 million (22.7% margin) and PAT at ₹126 million (15.5% margin). For H1FY27 standalone, revenue was ₹1,636 million, EBITDA at ₹375 million (22.9% margin), and PAT at ₹258 million (15.8% margin). EBITDA and EBITDA margin are reported before ESOP costs.
The company's organic momentum is strong, with MR productivity increasing by 10% and 7 out of the top 10 brands outperforming the market. Inorganically, the consolidation of Aequitas Healthcare (85% stake acquired for ₹208 million) from Q2 has opened up the hospital channel with access to over 1,000 hospitals. The acquisition of the Group Pharma Wellness Portfolio was completed on October 1, 2026, further strengthening the wellness segment.
Management commentary highlights a focus on building a platform for the next phase of growth. Investments were made in Q2 to strengthen the hospital team, integrate Aequitas, and support the wellness portfolio. These investments are expected to reflect in profitability from Q3FY27 onwards. Jagsonpal anticipates quarterly revenues to cross ₹1,000 million in Q3FY27 and remains on track to achieve its Mission 2028 target of ₹5,000 million in annual revenue. The company expressed confidence in adding more accretive transactions to accelerate this growth journey.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.